tetano
Editor, Senior Moderator
Vaccine. 2018 Sep 1. pii: S0264-410X(18)31186-1. doi: 10.1016/j.vaccine.2018.08.057. [Epub ahead of print]
[h=1]Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial.[/h] Mombelli M[SUP]1[/SUP], Rettby N[SUP]2[/SUP], Perreau M[SUP]2[/SUP], Pascual M[SUP]3[/SUP], Pantaleo G[SUP]2[/SUP], Manuel O[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The use of vaccines with higher doses of antigen is an attractive strategy to improve the immunogenicity of influenza vaccination in transplant recipients. However, the effect of vaccination with a double-dose (DD) containing 30 ?g of antigen in this population remains unknown.
[h=4]METHODS:[/h] We performed a randomized controlled trial to compare the immunogenicity and safety of DD (30 ?g) vs. standard dose (SD, 15 ?g) of a trivalent inactivated influenza vaccine in kidney and liver transplant recipients. Immunogenicity was assessed by hemagglutination-inhibition assay. Vaccine response was defined as seroconversion to at least one viral strain 2 weeks after vaccination and seroprotection as a titer ≥40.
[h=4]RESULTS:[/h] Sixty-three kidney and 16 liver transplant recipients were enrolled. Forty patients received the DD and 39 the SD vaccine. Overall, 40% of patients in the DD compared to 26% in the SD group (P = 0.174) responded to vaccine. In the DD arm, more patients were seroprotected to all viral strains after vaccination (88% vs 69%, P = 0.048). Post vaccination geometric mean titers of antibodies were 131.9 vs. 89.7 (P = 0.187) for H1N1, 185.4 vs. 138.7 (P = 0.182) for H3N2, and 96.6 vs. 68.8 (P = 0.081) for influenza B with the DD vs. SD. In both groups, most of the adverse events were mild and no vaccine-related severe adverse events were observed.
[h=4]CONCLUSION:[/h] Double-dose influenza vaccine is safe and may increase antibody response in transplant recipients. In this population, DD vaccination could be an alternative when high-dose vaccine is not available. NCT02746783.
Copyright ? 2018 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Double dose; Immunogenicity; Influenza vaccine; Transplant recipients
PMID: 30181045 DOI: 10.1016/j.vaccine.2018.08.057
[h=1]Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial.[/h] Mombelli M[SUP]1[/SUP], Rettby N[SUP]2[/SUP], Perreau M[SUP]2[/SUP], Pascual M[SUP]3[/SUP], Pantaleo G[SUP]2[/SUP], Manuel O[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The use of vaccines with higher doses of antigen is an attractive strategy to improve the immunogenicity of influenza vaccination in transplant recipients. However, the effect of vaccination with a double-dose (DD) containing 30 ?g of antigen in this population remains unknown.
[h=4]METHODS:[/h] We performed a randomized controlled trial to compare the immunogenicity and safety of DD (30 ?g) vs. standard dose (SD, 15 ?g) of a trivalent inactivated influenza vaccine in kidney and liver transplant recipients. Immunogenicity was assessed by hemagglutination-inhibition assay. Vaccine response was defined as seroconversion to at least one viral strain 2 weeks after vaccination and seroprotection as a titer ≥40.
[h=4]RESULTS:[/h] Sixty-three kidney and 16 liver transplant recipients were enrolled. Forty patients received the DD and 39 the SD vaccine. Overall, 40% of patients in the DD compared to 26% in the SD group (P = 0.174) responded to vaccine. In the DD arm, more patients were seroprotected to all viral strains after vaccination (88% vs 69%, P = 0.048). Post vaccination geometric mean titers of antibodies were 131.9 vs. 89.7 (P = 0.187) for H1N1, 185.4 vs. 138.7 (P = 0.182) for H3N2, and 96.6 vs. 68.8 (P = 0.081) for influenza B with the DD vs. SD. In both groups, most of the adverse events were mild and no vaccine-related severe adverse events were observed.
[h=4]CONCLUSION:[/h] Double-dose influenza vaccine is safe and may increase antibody response in transplant recipients. In this population, DD vaccination could be an alternative when high-dose vaccine is not available. NCT02746783.
Copyright ? 2018 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Double dose; Immunogenicity; Influenza vaccine; Transplant recipients
PMID: 30181045 DOI: 10.1016/j.vaccine.2018.08.057